Reni Benjamin
Stock Analyst at Citizens Capital Markets
(1.36)
# 3,181
Out of 4,817 analysts
184
Total ratings
35.48%
Success rate
-16.18%
Average return
Main Sectors:
Stocks Rated by Reni Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CUE Cue Biopharma | Reiterates: Market Outperform | $2 | $0.77 | +159.30% | 5 | Apr 2, 2025 | |
| BCAB BioAtla | Maintains: Market Outperform | $5 → $1 | $0.34 | +195.07% | 9 | Mar 31, 2025 | |
| INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $11.38 | - | 9 | Mar 18, 2025 | |
| ALLO Allogene Therapeutics | Upgrades: Market Outperform | $5 | $1.43 | +250.88% | 7 | Mar 14, 2025 | |
| INCY Incyte | Reiterates: Market Perform | n/a | $56.81 | - | 28 | Mar 11, 2025 | |
| ACET Adicet Bio | Reiterates: Market Perform | n/a | $0.57 | - | 5 | Mar 7, 2025 | |
| BPMC Blueprint Medicines | Reiterates: Market Outperform | $125 | $84.22 | +48.42% | 21 | Mar 3, 2025 | |
| BCYC Bicycle Therapeutics | Reiterates: Market Outperform | $26 | $7.59 | +242.56% | 13 | Feb 26, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Market Outperform | $12 → $4 | $0.84 | +373.71% | 5 | Jan 14, 2025 | |
| CGEN Compugen | Maintains: Market Outperform | $8 → $4 | $1.40 | +185.71% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $2.72 | - | 4 | Nov 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.40 | - | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $5.67 | - | 3 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $16 | $0.25 | +6,417.31% | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $10 | $19.64 | -49.08% | 2 | Oct 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $5 | $1.60 | +212.50% | 5 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.55 | - | 10 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $8 | $4.45 | +79.78% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $0.80 | +400.81% | 4 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $60 | $52.71 | +13.83% | 1 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $32 | $25.24 | +26.78% | 2 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $9.71 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $315 | $214.10 | +47.13% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $72.92 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $265 | $218.78 | +21.13% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $28 | $6.18 | +353.07% | 9 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $6 | $1.42 | +322.54% | 6 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $16.00 | - | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $25 → $23 | $3.08 | +646.75% | 10 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $28 → $17 | $3.22 | +428.77% | 3 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.35 | - | 3 | Nov 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | n/a | $6.67 | - | 4 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $1.38 | - | 2 | Feb 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $22 → $12 | $36.97 | -67.54% | 1 | Sep 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $9.63 | - | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.76 | - | 2 | Nov 10, 2017 |
Cue Biopharma
Apr 2, 2025
Reiterates: Market Outperform
Price Target: $2
Current: $0.77
Upside: +159.30%
BioAtla
Mar 31, 2025
Maintains: Market Outperform
Price Target: $5 → $1
Current: $0.34
Upside: +195.07%
Inhibrx Biosciences
Mar 18, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $11.38
Upside: -
Allogene Therapeutics
Mar 14, 2025
Upgrades: Market Outperform
Price Target: $5
Current: $1.43
Upside: +250.88%
Incyte
Mar 11, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $56.81
Upside: -
Adicet Bio
Mar 7, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $0.57
Upside: -
Blueprint Medicines
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $125
Current: $84.22
Upside: +48.42%
Bicycle Therapeutics
Feb 26, 2025
Reiterates: Market Outperform
Price Target: $26
Current: $7.59
Upside: +242.56%
Werewolf Therapeutics
Jan 14, 2025
Maintains: Market Outperform
Price Target: $12 → $4
Current: $0.84
Upside: +373.71%
Compugen
Aug 8, 2022
Maintains: Market Outperform
Price Target: $8 → $4
Current: $1.40
Upside: +185.71%
Nov 12, 2020
Upgrades: Market Perform
Price Target: n/a
Current: $2.72
Upside: -
Dec 3, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.40
Upside: -
Jun 14, 2019
Reinstates: Market Perform
Price Target: n/a
Current: $5.67
Upside: -
Oct 22, 2018
Maintains: Outperform
Price Target: $20 → $16
Current: $0.25
Upside: +6,417.31%
Oct 12, 2018
Maintains: Outperform
Price Target: $11 → $10
Current: $19.64
Upside: -49.08%
Mar 18, 2025
Upgrades: Market Outperform
Price Target: $5
Current: $1.60
Upside: +212.50%
Mar 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $0.55
Upside: -
Mar 12, 2025
Maintains: Market Outperform
Price Target: $7 → $8
Current: $4.45
Upside: +79.78%
Mar 12, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $0.80
Upside: +400.81%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $60
Current: $52.71
Upside: +13.83%
Feb 25, 2025
Reiterates: Market Outperform
Price Target: $32
Current: $25.24
Upside: +26.78%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $9.71
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $315
Current: $214.10
Upside: +47.13%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $72.92
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $265
Current: $218.78
Upside: +21.13%
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $6.18
Upside: +353.07%
Dec 11, 2024
Downgrades: Market Perform
Price Target: $6
Current: $1.42
Upside: +322.54%
Nov 4, 2024
Initiates: Market Perform
Price Target: n/a
Current: $16.00
Upside: -
Jun 20, 2024
Maintains: Market Outperform
Price Target: $25 → $23
Current: $3.08
Upside: +646.75%
Nov 10, 2020
Downgrades: Outperform
Price Target: $28 → $17
Current: $3.22
Upside: +428.77%
Nov 15, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $0.35
Upside: -
Jun 14, 2019
Reinstates: Outperform
Price Target: n/a
Current: $6.67
Upside: -
Feb 7, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $1.38
Upside: -
Sep 25, 2018
Downgrades: Outperform
Price Target: $22 → $12
Current: $36.97
Upside: -67.54%
Nov 15, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $9.63
Upside: -
Nov 10, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $1.76
Upside: -